A Phase 1b Multi-cohort Clinical Study of the Combination of Selumetinib (MK-5618) plus Pembrolizumab (MK-3475) alone or the Combination of Pembrolizumab plus Chemotherapy with or without MK-5618 in Participants with Metastatic Solid Tumors
Right-to-Try Use of ERC1671 to Treat Glioblastoma Multiforme (GBM) When Given in Combination with GM-CSF, Cyclophosphamide, Bevacizumab and Nivolumab in Patients who have Failed Prior Treatment with Radiation and Temozolomide
A Phase 1/2 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects with Relapsed or Refractory Multiple Myeloma
A Phase I Trial Assessing the Feasibility of Romidepsin Combined with Brentuximab Vedotin for Patients with Requiring Systemic Therapy for Cutaneous T-cell Lymphoma
A Phase 1, Multi-center, Open-label Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of an Orally Available Small Molecule, CC-99282, Alone and in Combination with Rituximab in Subjects with Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)
A Phase II Trial of PET-Directed Therapy using AVD (doxorubicin, vinblastine, and dacarbazine) plus Brentuximab Vedotin Induction Chemotherapy, with or without Brentuximab Vedotin plus Nivolumab, Followed by Nivolumab Consolidation for Patients with Previously Untreated Non-bulky Limited Stage Hodgkin Lymphoma
OXEL: A pilot study of immune checkpoint or capecitabine or combination therapy as adjuvant therapy for triple negative breast cancer with residual disease following neoadjuvant chemotherapy
A Phase II, Double Blind, Placebo Controlled Study of ACE-083 in Patients with Charcot-Marie-Tooth Disease Types 1 and X